Norwegian Court has ruled in the favor of Ranbaxy in a patent infringement lawsuit against Pfizer, contending that Ranbaxy’s proposed generic product would not infringe two of Pfizer’s Norwegian patents --- # 177,566 and # 180,199 --- covering a particular intermediate compound. However, this judgment does not have any immediate practical effect to Ranbaxy but will allow Ranbaxy to launch generic version of Lipitor by February 2009 rather than 2010. Pfizer has already planned to make an appeal against the decision. Pfizer has shown confidence in its Norwegian Patent # 177,706 expiring in February 2009 which was earlier upheld by Norwegian Court as valid and infringed by Ranbaxy’s proposed product. However, Ranbaxy has already made an appeal against the decision to the Norwegian Court of Appeals which is scheduled to be heard next March.